P

Phil

Digital platform enabling expedited prescription access

Registered Pharmacy Technician

Full-Time
$20 - $24/hr
Junior
Remote in USA+1 moreMore locations: San Francisco, CA, USA
RemoteRemote work is available only in the listed states.
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • An active Pharmacy Technician license in the state of residence is required.
  • National Pharmacy Technician Certification Board (PTCB) certification or Certified Pharmacy Technician (CPhT) credential is required.
  • At least one year of experience as a Pharmacy Technician in a retail, specialty, mail-order, pharmacy benefit manager, or healthcare-related environment is required.
  • Experience with prescription processing, insurance verification, claims resolution, prior authorizations, or medication access support is required.
  • A strong understanding of pharmacy operations and prescription workflows is required.
  • Ability to navigate multiple software systems, payer portals, and operational platforms simultaneously is required.
  • Strong written and verbal communication skills are required.
  • Organizational skills, attention to detail, and accuracy are required.
  • Ability to work independently while contributing effectively within a collaborative team environment is required.
  • A reliable high-speed internet connection and dedicated remote workspace are required.
Responsibilities
  • Process and enter electronic, faxed, and verbal prescription orders within pharmacy systems.
  • Review, verify, and update patient insurance information using payer portals and phone resources.
  • Determine when prior authorizations are required and submit authorization requests through payer-specific portals and vendor platforms.
  • Monitor, track, and troubleshoot prior authorization requests, claim rejections, denials, and escalations.
  • Resolve prescription processing issues by coordinating with provider offices, insurance carriers, and pharmacy partners.
  • Route and reroute prescriptions based on insurance requirements, pharmacy network restrictions, state regulations, transfer issues, and operational workflows.
  • Review clinical documentation for completeness and accuracy before authorization submission.
  • Navigate multiple pharmacy, operational, and vendor systems simultaneously while maintaining productivity and accuracy.
  • Document activities, communications, and case updates within company systems.
  • Collaborate with internal teams to address patient access barriers, pharmacy inventory issues, system outages, and other operational challenges.
  • Communicate with prescribers, pharmacies, insurance carriers, and internal stakeholders to resolve issues in a timely manner.
  • Follow established workflows, quality standards, and compliance requirements while maintaining productivity expectations.
  • Support additional operational functions as business needs require.
Desired Qualifications
  • Experience with specialty pharmacy, manufacturer support programs, or patient access services is preferred.
  • Working knowledge of insurance claim rejections and override processes is preferred.
  • Working knowledge of prior authorizations and appeals is preferred.
  • Working knowledge of ICD-10 codes and prescription drug terminology is preferred.
  • Working knowledge of Medicare, Medicaid, and commercial insurance plans is preferred.
  • Working knowledge of pharmacy claims adjudication and reimbursement processes is preferred.
  • Working knowledge of FSA/HSA payment considerations is preferred.
  • Customer service or patient support experience is preferred.

About the company

Phil.us offers PhilRx, a digital health platform that streamlines obtaining prescribed medications for patients and helps providers manage care. It coordinates clinicians, payers, and pharmacies through a national dispense network, real-time HIPAA-compliant data, and workflows for prior authorization and formulary access. It stands out by delivering an integrated medication-access workflow along with consulting services and telemedicine, not just software. Its goal is to improve patient adherence and increase insured prescriptions while earning revenue from platform subscriptions, consulting services, and potential per-prescription economics.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$158.6M

Headquarters

Scottsdale, Arizona

Founded

2015

Get referred to Phil

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 cash-dispense expansion increases throughput for New Day, YUVEZZI, and Addyi programs.
  • PHIL reported 150% 2024 net revenue growth and 10x prescription volume since 2021.
  • AI-driven workflows and 2026 funding support broader customer expansion and faster program deployment.

What critics are saying

  • PHIL depends on partner launches; losing Tenpoint or Sprout would cut pipeline quickly.
  • K2 HealthVentures debt adds repayment pressure if growth slows before 2027.
  • Direct-to-patient margins face PBM, payer, and specialty-pharmacy retaliation as brands internalize access.

What makes Phil unique

  • PHIL owns a direct-to-patient workflow spanning intake, fulfillment, analytics, and cash pharmacy.
  • 2026 launches with Tenpoint, Sprout, and Evolved Health prove repeatable brand partnerships.
  • PHIL’s nationwide network claims 99%+ plan coverage across all 50 states and territories.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

1%
Associated Press
Sep 1st, 2026
PHIL and Evolved Health launch New Day Skin Spray direct-to-patient programme for atopic dermatitis

PHIL, a technology-powered patient access platform, has partnered with Evolved Health to launch the New Day™ Skin Spray Direct-to-Patient programme. The prescription topical emulsion spray treats mild to severe atopic dermatitis and is now available in select US markets, with a broader national rollout planned. The therapy uses peptide technology from Evolved By Nature, developed into a medical device by Evolved Health. It can be used alone or alongside other treatments, with no washout periods or systemic exposure required. Atopic dermatitis affects an estimated 19.8 million adults and 9.2 million children in the United States. Research shows over 40% of diagnosed patients pay more than $1,000 annually in out-of-pocket treatment costs. Patients prescribed the spray pay a $15 copay with no prior authorisation required. The product ships free within three to five days.

Business Wire
Apr 2nd, 2026
Tenpoint Therapeutics partners with PHIL to launch direct-to-patient cash program for YUVEZZI presbyopia therapy

Tenpoint Therapeutics and PHIL Inc. have launched a direct-to-patient cash programme for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia treatment. The programme aims to improve access to the therapy through affordable pricing, home delivery and dedicated support. Presbyopia affects nearly 128 million Americans and approximately 2 billion people globally, with many patients going untreated due to high out-of-pocket costs and limited access. The partnership seeks to reduce these barriers and support long-term treatment adherence. YUVEZZI contains carbachol and brimonidine tartrate ophthalmic solution at 2.75%/0.1% concentration. PHIL operates a healthcare technology platform that connects pharmaceutical manufacturers with patients to provide more convenient and affordable medication access.

PharmiWeb
Apr 2nd, 2026
Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable.

Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable. SCOTTSDALE, Ariz.-(BUSINESS WIRE)-Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI(TM), the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Why Direct-to-Patient Access Matters for Presbyopia Patients Access and adherence remain persistent challenges in ophthalmology, where treatments are often underutilized due to a complex patient journey with high affordability barriers. Presbyopia, an ophthalmic condition that affects nearly 128 million Americans and approximately 2 billion people globally, has traditionally seen patients go untreated due to high out-of-pocket costs and limited therapy access (AOA, 2023). The opportunity to help meaningfully improve access to presbyopia therapy for millions of patients has never been greater. Modernizing the Access Journey for YUVEZZI(TM) Tenpoint and PHIL have partnered to launch an innovative DTP program, delivering YUVEZZI(TM) directly to patients through a seamless access experience with affordable, transparent pricing, home delivery, and dedicated support. This groundbreaking partnership reflects our shared commitment to improving how presbyopia patients receive therapy through reducing access barriers, lowering out-of-pocket costs, and supporting long-term treatment adherence for presbyopia patients. "We are excited to partner with Tenpoint Therapeutics as they launch YUVEZZI(TM)- a meaningful leap forward for presbyopia patients across the country. For the 128 million Americans living with this condition, our direct-to-patient program provides a seamless and accessible path to this innovative therapy. This partnership demonstrates what's possible when patient access is a top priority." - Deepak Thomas, CEO & Founder, PHIL About Tenpoint: Tenpoint Therapeutics Ltd. is an ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.[1,2] By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. For more information, visit tenpointtherapeutics.com. About PHIL Inc.: PHIL is a healthcare technology platform that partners with pharmaceutical manufacturers to empower patients with more convenient and affordable access to their prescribed medications. Through PHIL's digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale. For more information, visit phil.us. [1] American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf. [2] Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492-9. Editor details. * Company: * Businesswire Last Updated: 02-Apr-2026

FinSMEs
Jul 9th, 2025
Phil Receives $60M Growth Capital Facility from K2 HealthVentures

Phil receives $60M growth capital facility from K2 HealthVentures.

Health Technology Insights
Jul 8th, 2025
Phil Secures $60 Million Growth Capital from K2 HealthVentures to Boost AI Integration

Phil, a leading software-driven pharmaceutical commercialization platform, announced a $60 million growth debt financing from K2 HealthVentures, a healthcare and life sciences-focused investment firm.